Trading Signals: IOVA Stock Price Prediction and Forecast (Mon. Aug. 10, 2015 - Wed. Sep. 27, 2023)(Iovance Biotherapeutics Inc)
| IOVA latest price $44.6400 (-3.19%) ($44.6400 - $44.6400) on Tue. Jan. 5, 2021. | |
| | Trend Analysis and Forecast | | | Average Daily Percentage Swing | 3.43% (three month average) | RSI | 34 | Latest Price | $44.6400(-3.19%) | Stocks Behave Similarly | Similar Stock List | Daily Trend | IOVA declines -1.5% a day on average for past five trading days. | Weekly Trend | IOVA declines -1% a week on average for past two weeks. | Market Behavior | Broad based rally for large cap. Broad based rally for small cap. | Correlated ETFs | Broad market will support IOVA advance at 0% a week (0% probability) IBB(48%) XBI(45%) ARKG(43%) IWO(42%) ARKK(39%) | Factors Impacting IOVA price | IOVA will decline at least -1.715% in a week (0% probabilities). VIXM(-23%) UUP(-16%) VXX(-12%) TBT(-6%) UNG(-2%) | | | | | Relative Volatility | (options are extremely cheap) | | | Market Trend Strength | -1.715% (StdDev 3.43%) | Hourly BBV | -1.6 () | Intraday Trend | 0% | | | |
|
Resistance Level | $47.75 | 5 Day Moving Average | $46.7(-4.41%) | 10 Day Moving Average | $47.81(-6.63%) | 20 Day Moving Average | $47.75(-6.51%) | To recent high | -10.9% | To recent low | 59% | Market Cap | $6.537b | | | | Iovance Biotherapeutics, Inc. operates as a biotechnology company. The firm engages in the development and commercialization of novel cancer immunotherapy products. Its lead product candidate, LN-144 for metastatic melanoma, is an autologous adoptive cell therapy utilizing tumor-infiltrating lymphocytes, or TIL, which are T cells derived from patients' tumors. The company was founded by Robert T. Brooke on September 17, 2007 and is headquartered in San Carlos, CA. |